Previous close | 3.5000 |
Open | 3.5000 |
Bid | 2.3000 |
Ask | 6.0000 |
Strike | 100.00 |
Expiry date | 2025-01-17 |
Day's range | 3.5000 - 3.5000 |
Contract range | N/A |
Volume | |
Open interest | 9 |
Novartis (NVS) Kisqali meets primary endpoint of invasive disease-free survival in certain patients with early breast cancer at risk of recurrence.
Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).